Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 mai 2026 16h05 HE | Source: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
07 mai 2026 19h00 HE | Source: PyroGenesis Inc.

PyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% Year-Over-Year for Best Quarter Since 2022

Strong start to year leads to second highest Q1 revenue in Company’s history.Advancement and completion of major projects drive Q1 revenue.Backlog of $43.1 million. MONTREAL, May 07, 2026 (GLOBE...
20 avr. 2026 08h00 HE | Source: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE...
30 mars 2026 23h00 HE | Source: PyroGenesis Inc.

PyroGenesis Announces Fourth Quarter and Full Year 2025 Results

MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX:PYR) (OTCQX:PYRGF) (FRA:8PY1), a leader in ultra-high temperature processes & engineering...
25 mars 2026 07h31 HE | Source: Vanderbilt Report and Artelo Biosciences

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a...
24 mars 2026 08h00 HE | Source: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for...
16 mars 2026 11h17 HE | Source: Mordor Intelligence

Solar Panel Recycling Market – 9%+ CAGR Forecast for 2026–2031 Amid Rising Solar PV Waste and Strengthening Recycling Regulations, Reports Mordor Intelligence

Hyderabad, March 16, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the solar panel recycling market was valued at USD 421.94 million in 2025 and is projected to grow from USD 461.11...
10 mars 2026 08h00 HE | Source: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ’s strategy to expand global access to VIZZ Submission of MAA in Europe results in the fifth ex-U.S....
06 mars 2026 07h30 HE | Source: Mordor Intelligence

Aerogel Market to Hit USD 1.59 Billion by 2031 as Energy, Construction, and Mobility Sectors Increase Adoption of Advanced Insulation Materials, Says Mordor Intelligence

Hyderabad , March 06, 2026 (GLOBE NEWSWIRE) -- According to the latest report from Mordor Intelligence, the global aerogel market is expected to grow from USD 0.90 billion in 2025 to USD 0.99...
24 févr. 2026 08h00 HE | Source: Artelo Biosciences

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

SOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

Page suivante